Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

INTRODUCTION: Parkinson’s disease (PD) is a common neurodegenerative disorder with substantial morbidity. No disease-modifying treatments currently exist. The glucagon like peptide-1 receptor agonist exenatide has been associated in single-centre studies with reduced motor deterioration over 1 year....

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:BMJ Open
Main Authors: Vijiaratnam, Nirosen, Girges, Christine, Auld, Grace, Chau, Marisa, Maclagan, Kate, King, Alexa, Skene, Simon, Chowdhury, Kashfia, Hibbert, Steve, Morris, Huw, Limousin, Patricia, Athauda, Dilan, Carroll, Camille B, Hu, Michele T, Silverdale, Monty, Duncan, Gordon W, Chaudhuri, Ray, Lo, Christine, Del Din, Silvia, Yarnall, Alison J, Rochester, Lynn, Gibson, Rachel, Dickson, John, Hunter, Rachael, Libri, Vincenzo, Foltynie, Thomas
Format: Artigo
Sprog:Inglês
Udgivet: BMJ Publishing Group 2021
Fag:
Neurology
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8166598/
https://ncbi.nlm.nih.gov/pubmed/34049922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-047993
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker